Preuves provenant d’autres sources que l’ACMTS
Gouvernement du Canada et associations
- University of Calgary Health Technology Assessment Unit. 2017. Cannabis evidence series: An evidence synthesis.
- Gouvernement du Canada, ministère de la Justice. Règlement sur l’accès au cannabis à des fins médicales (SOR/2016-230); 2017.
- Santé Canada. Un cadre pour la légalisation et la réglementation du cannabis au Canada: Le rapport final du Groupe de travail sur la légalisation et la réglementation du cannabis; 2016. Chapitre 5 – Accès médical.
- Santé Canada. Le cannabis (marihuana, marijuana) et les cannabinoïdes: Plante séchée aux fins d’administration par ingestion ou par d’autres moyens (agent psychoactif); 2013.
- Santé Canada. Renseignements pour les praticiens de la santé; 2016.
- RxFiles. Cannabinoïdes: tableau comparatif du médicament; 2017 (en anglais seulement).
- Le Collège des médecins de famille du Canada. Autorisation du cannabis déshydraté pour le traitement de la douleur chronique ou de l’anxiété : orientation préliminaire; 2014.
- Le centre canadien sur les dépendances et l'usage de substances [CCDUS]. Dissiper la fumée entourant le cannabis: usage de cannabis et de cabinnoïdes à des fins médicinales - version actualisée; 2016.
- Le centre canadien sur les dépendances et l'usage de substances [CCDUS]. Cannabis. 2016.
- Le centre canadien sur les dépendances et l'usage de substances [CCDUS]. Usage de la marijuana à des fins médicales [notes sur les politiques]. 2015.
- L'Association canadienne de protection médicale [ACPM]. La marihuana à des fins médicales : ce que les médecins canadiens devraient prendre en considération. Mai 2014.
Les 4 documents suivants ne sont accessibles qu'en anglais.
- KPMG (prepared for Canadian Pharmacists Association). Improving medical marijuana management in Canada; 2016.
- Alberta Health Services. Cannabis (marijuana): information for health professionals; 2015.
- Canadian Pharmacists Association. Medical marijuana: position statement; 2016.
- Workers Compensation Board of Nova Scotia. Clinical efficacy of medical marijuana: summary of evidence‐based research; 2011 [update].
Articles de revues
- Fischer et al. Lower-Risk Cannabis Use Guidelines: A Comprehensive Update of Evidence and Recommendations. American Journal of Public Health, 2017; e1. dx.doi.org/10.2105/AJPH.2017.303818.
- Wettlaufer et al. Estimating the harms and costs of cannabis-attributable collisions in the Canadian provinces. Drug and Alcohol Dependence; 2017;173:185-190. dx.doi.org/10.1016/j.drugalcdep.2016.12.024
- Devinsky et al. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. N Engl J Med; 2017;376:2011-2020. dx.doi.org/10.1056/NEJMoa1611618
- West, JC. Medical marijuana: Challenges and risk issues for health care providers. J of Healthcare Risk Mgmt; 2017;36:38-43. dx.doi.org/10.1002/jhrm.21267
- Hazekamp A, Heerdink, ER. The prevalence and incidence of medicinal cannabis on prescription in The Netherlands. Eur J Clin Pharmacol; 2013 Aug;69(8):1575-80. ncbi.nlm.nih.gov/pubmed/23588562
- Hazekamp A, Ware MA, Muller-Vahl KR, Abrams D, Grotenhermen F. The medicinal use of cannabis and cannabinoids--an international cross-sectional survey on administration forms. J Psychoactive Drugs. 2013 Jul-Aug;45(3):199-210. ncbi.nlm.nih.gov/pubmed/24175484
- Ko GD, Bober SL, Mindra S, Moreau JM. Medical cannabis - the Canadian perspective. J Pain Res 2016; 9:735-44. ncbi.nlm.nih.gov/pmc/articles/PMC5053383
- Kahan M, Srivastava A, Spithoff S, Bromley L. Prescribing smoked cannabis for chronic noncancer pain: preliminary recommendations. Can Fam Physician. 2014 Dec; 60(12):1083-90. ncbi.nlm.nih.gov/pmc/articles/PMC4264803/
- Lucas, P. Cannabis as an Adjunct to or Substitute for Opiates in the Treatment of Chronic Pain, Journal of Psychoactive Drugs, 2012, 44:2, 125-133. doi:10.1080/02791072.2012.684624
- Lucas et al. Cannabis as a substitute for alcohol and other drugs: A dispensary-based survey of substitution effect in Canadian medical cannabis patients. Addiction Research and Theory, 2013, 21(5): 435–442. dx.doi.org/10.3109/16066359.2012.733465
- Lucas et al. Substituting cannabis for prescription drugs, alcohol and other substances among medical cannabis patients: The impact of contextual factors. Drug and Alcohol Review, 2015. ncbi.nlm.nih.gov/pubmed/26364922.
- Lucas, P., Walsh, Z. Medical cannabis access, use, and substitution for prescription opioids and other substances: A survey of authorized medical cannabis patients. International Journal of Drug Policy, 2017, 42, 30–35. ncbi.nlm.nih.gov/pubmed/28189912
- Rubin, R. Medical marijuana is legal in most states, but physicians have little evidence to guide them. JAMA. 2017; 317(16):1611-1613. jamanetwork.com/journals/jama/fullarticle/2617326
Examens méthodiques
- Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015 Jun 23;313(24):2456-73. jamanetwork.com/journals/jama/fullarticle/2338251
- Tsang CC, Giudice MG. Nabilone for the management of pain. Pharmacotherapy. 2016 Mar; 36(3):273-86. ncbi.nlm.nih.gov/pubmed/26923810
- Deshpande A, Mailis-Gagnon A, Zoheiry N, Lakha SF. Efficacy and adverse effects of medical marijuana for chronic noncancer pain: systematic review of randomized controlled trials. Can Fam Phys; 2015 Aug;61(8):e372-81. ncbi.nlm.nih.gov/pubmed/26505059
- Gloss D, Vickrey B. Cannabinoids for epilepsy; 2014. cochranelibrary.com/enhanced/doi/10.1002/14651858.CD009270.pub3
- Koppel BS, Brust JCM, Fife T, Bronstein J, Youssof S, Gronseth G, et al. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders (Report of the Guideline Development Subcommittee of the American Academy of Neurology. 2014;82(17):1556-1563. neurology.org/content/82/17/1556.full.pdf+html
Énoncés de politiques et d'orientation
Canada
- L'Association médicale canadienne. La marijuana à des fins médicales (énoncé de politique) 2011.
- Medical marijuana American Academy of Child Adolescent Psychiatry; 2012 Jun.
- British Columbia Pharmacy Association. Medical marijuana; 2017.
- Collège des médecins du Québec. Directives concernant l’ordonnance de cannabis séché à des fins médicales. 2014.
International
- Federation of State Medical Records. Model guidelines for the recommendation of marijuana in patient care; 2016.
- Australian Government - Department of Health. Current status of Medicinal Cannabis. Special Access Scheme Category A access to medicinal cannabis products; 2017.
- Medicinal cannabis; 2016. [The Narcotic Drugs Amendment Bill was passed by the Australian Parliament on 24 February 2016. The Narcotic Drugs Amendment Act 2016 enables a sustainable supply of safe medicinal cannabis products to Australian patients.]
- GW Pharma to test cannabinoids in cancer; 2017 Feb.
- Marijuana as medicine National Institute on Drug Abuse, National Institutes of Health, U.S. Department of Health and Human Services; 2017 Mar.
- International Association for the Study of Pain. Medical Cannabis and Pain. Pain Clinical Updates, VOL XXII(3); 2014 Oct.